This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olsson, A.-K. Articles by Claesson-Welsh, L. Search for Related Content PubMed PubMed Citation Articles by Olsson, A.-K. Articles by Claesson-Welsh, L.

A Fragment of Histidine-Rich Glycoprotein Is a Potent Inhibitor of Tumor Vascularization

¹ Department of Genetics and Pathology, Uppsala University, Rudbeck Laboratory, Uppsala;
² Innoventus Project AB, Uppsala; and
³ Department of Veterinary Medical Chemistry, Swedish University of Agricultural Sciences, Biomedical Center, Uppsala, Sweden

In this study, we show that recombinant human histidine-rich glycoprotein (HRGP) has potent antiangiogenic properties as judged from effects on a syngeneic tumor model in C57/bl6 mice. Growth of fibrosarcoma, a very aggressive tumor, was reduced by >60% by HRGP treatment, and tumor angiogenesis was dramatically decreased. Treatment with HRGP led to increased apoptosis and reduced proliferation in the tumors. In contrast, HRGP did not affect apoptosis or DNA synthesis in endothelial cells or tumor cells in vitro. The mechanism of action of HRGP involves rearrangement of focal adhesions and decreased attachment of endothelial cells to vitronectin and, as a consequence, reduced endothelial cell migration. By using truncated versions of HRGP, we demonstrate that the isolated 150 amino acid-residue His/Pro-rich domain, which is also released by spontaneous proteolysis from purified HRGP, mediates the inhibitory effect on chemotaxis. Moreover, the His/Pro-rich domain must be released from HRGP to exert its effect. This study shows for the first time inhibitory effects of HRGP on tumor vascularization in vivo, thus providing proof of concept that HRGP is an angiogenesis inhibitor.

This article has been cited by other articles:

				Z. Li, M. A. Nardi, Y.-S. Li, W. Zhang, R. Pan, S. Dang, H. Yee, D. Quartermain, S. Jonas, and S. Karpatkin C-terminal ADAMTS-18 fragment induces oxidative platelet fragmentation, dissolves platelet aggregates, and protects against carotid artery occlusion and cerebral stroke Blood, June 11, 2009; 113(24): 6051 - 6060. [Abstract] [Full Text] [PDF]

				T. Sakai, K. Balasubramanian, S. Maiti, J. B. Halder, and A. J. Schroit Plasmin-Cleaved {beta}-2-Glycoprotein 1 Is an Inhibitor of Angiogenesis Am. J. Pathol., November 1, 2007; 171(5): 1659 - 1669. [Abstract] [Full Text] [PDF]

				M. Vanwildemeersch, A.-K. Olsson, E. Gottfridsson, L. Claesson-Welsh, U. Lindahl, and D. Spillmann The Anti-angiogenic His/Pro-rich Fragment of Histidine-rich Glycoprotein Binds to Endothelial Cell Heparan Sulfate in a Zn2+-dependent Manner J. Biol. Chem., April 14, 2006; 281(15): 10298 - 10304. [Abstract] [Full Text] [PDF]

				J. Dixelius, A.-K. Olsson, A. Thulin, C. Lee, I. Johansson, and L. Claesson-Welsh Minimal Active Domain and Mechanism of Action of the Angiogenesis Inhibitor Histidine-Rich Glycoprotein Cancer Res., February 15, 2006; 66(4): 2089 - 2097. [Abstract] [Full Text] [PDF]

				A. L. Jones, I. K. H. Poon, M. D. Hulett, and C. R. Parish Histidine-rich Glycoprotein Specifically Binds to Necrotic Cells via Its Amino-terminal Domain and Facilitates Necrotic Cell Phagocytosis J. Biol. Chem., October 21, 2005; 280(42): 35733 - 35741. [Abstract] [Full Text] [PDF]

				A.-K. Olsson, I. Johansson, H. Akerud, B. Einarsson, R. Christofferson, T. Sasaki, R. Timpl, and L. Claesson-Welsh The Minimal Active Domain of Endostatin Is a Heparin-Binding Motif that Mediates Inhibition of Tumor Vascularization Cancer Res., December 15, 2004; 64(24): 9012 - 9017. [Abstract] [Full Text] [PDF]

				F. Donate, J. C. Juarez, X. Guan, N. V. Shipulina, M. L. Plunkett, Z. Tel-Tsur, D. E. Shaw, W. T. Morgan, and A. P. Mazar Peptides Derived from the Histidine-Proline Domain of the Histidine-Proline-Rich Glycoprotein Bind to Tropomyosin and Have Antiangiogenic and Antitumor Activities Cancer Res., August 15, 2004; 64(16): 5812 - 5817. [Abstract] [Full Text] [PDF]

				A. L. Jones, M. D. Hulett, and C. R. Parish Histidine-rich Glycoprotein Binds to Cell-surface Heparan Sulfate via Its N-terminal Domain following Zn2+ Chelation J. Biol. Chem., July 16, 2004; 279(29): 30114 - 30122. [Abstract] [Full Text] [PDF]